Literature DB >> 29249563

Design and synthesis of pyrazolopyridine derivatives as sphingosine 1-phosphate receptor 2 ligands.

Zonghua Luo1, Xuyi Yue1, Hao Yang1, Hui Liu1, Robyn S Klein2, Zhude Tu3.   

Abstract

Eleven new sphingosine 1-phosphate receptor 2 (S1PR2) ligands were synthesized by modifying lead compound N-(2,6-dichloropyridin-4-yl)-2-(4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)hydrazine-1-carboxamide (JTE-013) and their binding affinities toward S1PRs were determined in vitro using [32P]S1P and cell membranes expressing recombinant human S1PRs. Among these ligands, 35a (IC50 = 29.1 ± 2.6 nM) and 35b (IC50 = 56.5 ± 4.0 nM) exhibit binding potency toward S1PR2 comparable to JTE-013 (IC50 = 58.4 ± 7.4 nM) with good selectivity for S1PR2 over the other S1PRs (IC50 > 1000 nM). Further optimization of these analogues may identify additional and more potent and selective compounds targeting S1PR2.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Binding affinities; Multiple sclerosis; Selectivity; Sphingosine 1-phosphate receptor 2

Mesh:

Substances:

Year:  2017        PMID: 29249563      PMCID: PMC8781228          DOI: 10.1016/j.bmcl.2017.12.010

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  21 in total

1.  The immune modulator FTY720 targets sphingosine 1-phosphate receptors.

Authors:  Volker Brinkmann; Michael D Davis; Christopher E Heise; Rainer Albert; Sylvain Cottens; Robert Hof; Christian Bruns; Eva Prieschl; Thomas Baumruker; Peter Hiestand; Carolyn A Foster; Markus Zollinger; Kevin R Lynch
Journal:  J Biol Chem       Date:  2002-04-19       Impact factor: 5.157

Review 2.  International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.

Authors:  Jerold Chun; Timothy Hla; Kevin R Lynch; Sarah Spiegel; Wouter H Moolenaar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  Discovery of novel S1P2 antagonists, part 3: Improving the oral bioavailability of a series of 1,3-bis(aryloxy)benzene derivatives.

Authors:  Kensuke Kusumi; Koji Shinozaki; Yoshiyuki Yamaura; Ai Hashimoto; Haruto Kurata; Atsushi Naganawa; Kazuhiro Otsuki; Takeshi Matsushita; Tetsuya Sekiguchi; Akito Kakuuchi; Hiroshi Yamamoto; Takuya Seko
Journal:  Bioorg Med Chem Lett       Date:  2016-01-12       Impact factor: 2.823

4.  Assessing the bioisosterism of the trifluoromethyl group with a protease probe.

Authors:  Monika Jagodzinska; Florent Huguenot; Gabriele Candiani; Matteo Zanda
Journal:  ChemMedChem       Date:  2009-01       Impact factor: 3.466

Review 5.  International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature.

Authors:  Jerold Chun; Edward J Goetzl; Timothy Hla; Yasuyuki Igarashi; Kevin R Lynch; Wouter Moolenaar; Susan Pyne; Gabor Tigyi
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

6.  Cognitive and psychiatric comorbidities in neuromyelitis optica.

Authors:  Perry Moore; Abigail Methley; Catherine Pollard; Kerry Mutch; Shahd Hamid; Liene Elsone; Anu Jacob
Journal:  J Neurol Sci       Date:  2015-11-18       Impact factor: 3.181

7.  Discovery of novel S1P2 antagonists. Part 2: Improving the profile of a series of 1,3-bis(aryloxy)benzene derivatives.

Authors:  Kensuke Kusumi; Koji Shinozaki; Yoshiyuki Yamaura; Ai Hashimoto; Haruto Kurata; Atsushi Naganawa; Hideyuki Ueda; Kazuhiro Otsuki; Takeshi Matsushita; Tetsuya Sekiguchi; Akito Kakuuchi; Takuya Seko
Journal:  Bioorg Med Chem Lett       Date:  2015-09-08       Impact factor: 2.823

8.  Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist.

Authors:  Makoto Osada; Yutaka Yatomi; Tsukasa Ohmori; Hitoshi Ikeda; Yukio Ozaki
Journal:  Biochem Biophys Res Commun       Date:  2002-12-06       Impact factor: 3.575

9.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

10.  A sphingosine 1-phosphate receptor 2 selective allosteric agonist.

Authors:  Hideo Satsu; Marie-Therese Schaeffer; Miguel Guerrero; Adrian Saldana; Christina Eberhart; Peter Hodder; Charmagne Cayanan; Stephan Schürer; Barun Bhhatarai; Ed Roberts; Hugh Rosen; Steven J Brown
Journal:  Bioorg Med Chem       Date:  2013-06-15       Impact factor: 3.641

View more
  4 in total

1.  Design, synthesis, and in vitro bioactivity evaluation of fluorine-containing analogues for sphingosine-1-phosphate 2 receptor.

Authors:  Zonghua Luo; Hui Liu; Robyn S Klein; Zhude Tu
Journal:  Bioorg Med Chem       Date:  2019-06-29       Impact factor: 3.641

2.  Synthesis and evaluation of highly selective quinazoline-2,4-dione ligands for sphingosine-1-phosphate receptor 2.

Authors:  Zonghua Luo; Hui Liu; Yanbo Yu; Robert J Gropler; Robyn S Klein; Zhude Tu
Journal:  RSC Med Chem       Date:  2022-01-03

3.  Synthesis and characterization of [125I]TZ6544, a promising radioligand for investigating sphingosine-1-phosphate receptor 2.

Authors:  Zonghua Luo; Qianwa Liang; Hui Liu; Joshi Sumit; Hao Jiang; Robyn S Klein; Zhude Tu
Journal:  Nucl Med Biol       Date:  2020-07-27       Impact factor: 2.408

4.  Synthesis of Highly Potent Anti-Inflammatory Compounds (ROS Inhibitors) from Isonicotinic Acid.

Authors:  Sana Yaqoob; Nourina Nasim; Rahila Khanam; Yan Wang; Almas Jabeen; Urooj Qureshi; Zaheer Ul-Haq; Hesham R El-Seedi; Zi-Hua Jiang; Farooq-Ahmad Khan
Journal:  Molecules       Date:  2021-02-26       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.